Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma
Latest Information Update: 18 Aug 2023
At a glance
- Drugs Alpelisib (Primary) ; Sotrastaurin (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions
Most Recent Events
- 11 Aug 2023 Number of treatment arms increased from 1 to 5 by the addition of separate arms for separate doses
- 11 Aug 2023 Status changed from active, no longer recruiting to completed.
- 21 Dec 2017 Status changed from recruiting to active, no longer recruiting.